BeOne Medicines Ltd. 4

CEO John Oyler of BeOne Medicines Ltd. exercised 33,990 ADSs and sold roughly 109,713 ADSs of BeOne Medicines (ONC) around $310–$320 per ADS on July 20–21, 2026 under a Rule 10b5‑1 plan.

On July 20–21, 2026, John Oyler, Chief Executive Officer of BeOne Medicines Ltd., executed a series of transactions in the company’s American Depositary Shares (ADSs). On July 20, he exercised options covering 33,990 ADSs (equivalent to 441,870 ordinary shares) at an implied exercise price of $119.96 per ADS, adding those shares to his direct holdings, and then sold a substantial portion of ADSs in multiple 10b5‑1 plan sales across two days. On July 20 he sold 5,146 ADSs at $310.0812, 6,273 ADSs at $310.7461, 2,907 ADSs at $311.7952, 15,499 ADSs at $312.2856, 14,326 ADSs at $312.9578, 1,850 ADSs at $313.909, 1,512 ADSs at $315.263, 523 ADSs at $316.1363, and 280 ADSs at $318.30, and on July 21 he sold 15,379 ADSs at $316.2602, 20,029 ADSs at $316.9075, 7,842 ADSs at $318.4133, 15,807 ADSs at $319.2901, and 2,340 ADSs at $320.0583; each reported price represents a weighted average over multiple trades within narrow ranges as disclosed in the footnotes. In total, Oyler exercised 33,990 ADSs and sold approximately 109,713 ADSs at prices around $310–$320 per ADS pursuant to a pre‑arranged Rule 10b5‑1 trading plan, leaving him with zero ADSs directly held after the final reported sale, though he retains significant indirect and ordinary share holdings, including various trust and LLC structures for which he disclaims beneficial ownership except as noted.

Filing Facts

CIK

1651308

Ticker

ONC

Form

4

Source Type

fda

Accession

0001042047-26-000017

Alert Tier

7